Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T15:42:56.276Z.
Calculation as of: 2026-10-06T15:42:56.276Z.
Quote observation: 2026-10-06T15:40:04.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5b41231b7583dd96ab78187317b9f32b3728f458d8f95d0d00832bd8f136f307
PEG RATIO
N/A
Neumora Therapeutics, Inc. Common Stock
Market Cap
$94.46M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| Neumora Therapeutics, Inc. Common Stock (NMRA) | $94.46M | N/A |
| Conexeu Sciences Inc. (CNXU)vs › | $94.35M | N/A |
| Biomea Fusion, Inc. (BMEA)vs › | $93.27M | N/A |
| Park Dental Partners, Inc. Common Stock (PARK)vs › | $96.58M | N/A |
| Equillium, Inc. (EQ)vs › | $92.31M | N/A |
| Milestone Pharmaceuticals Inc. (MIST)vs › | $97.48M | N/A |
| electroCore, Inc. (ECOR)vs › | $91.15M | N/A |
| PolyPid Ltd. (PYPD)vs › | $98.56M | N/A |
| Korro Bio, Inc. (KRRO)vs › | $98.69M | N/A |
| PMV Pharmaceuticals, Inc. (PMVP)vs › | $89.86M | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
